Enanta Pharma: EC Grants Marketing Authorizations For AbbVie's VIEKIRAX

(RTTNews) - Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, said the European Commission has granted marketing authorizations for AbbVie's VIEKIRAX + EXVIERA with or without ribavirin or RBV for the treatment of patients with genotype 1 or GT1 chronic hepatitis C virus or HCV infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. Also, the European Commission has also approved VIEKIRAX for use with RBV for the treatment of patients with genotype 4 or GT4 chronic HCV infection.

Paritaprevir, formerly known as ABT-450, is Enanta's lead protease inhibitor identified within the ongoing Enanta-AbbVie collaboration and is one of two direct-acting antivirals or DAAs in the VIEKIRAX tablet. AbbVie (ABBV) is responsible for all worldwide development and commercialization of VIEKIRAX-containing regimens and other regimens containing paritaprevir.